Resveratrol inhibits protein translation in hepatic cells

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Villa Cuesta, Eugenia ^a   Boylan, Joan M ^b   Tatar, Marc ^a   Gruppuso, Philip A ^b  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INITIATION FACTOR 2ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN KINASE B; RESVERATROL; S6 KINASE; S6 KINASE 1; UNCLASSIFIED DRUG; INITIATION FACTOR 2; INITIATION FACTOR 4F; PROTEIN KINASE INHIBITOR; RAPAMYCIN; STILBENE DERIVATIVE; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; INHIBITION KINETICS; LIVER CELL; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; PROTEIN SYNTHESIS REGULATION; RAT; SIGNAL TRANSDUCTION; TRANSLATION INITIATION; TRANSLATION REGULATION; ANIMAL; CELL PROLIFERATION; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN SYNTHESIS;

MAMMALIA; RATTUS;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; EUKARYOTIC INITIATION FACTOR-2; EUKARYOTIC INITIATION FACTOR-4F; LIVER; LIVER NEOPLASMS; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; PROTEIN KINASE INHIBITORS; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-AKT; RATS; SIGNAL TRANSDUCTION; SIROLIMUS; STILBENES; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS;

EID: 84855262938     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029513     Document Type: Article

References (80)

1. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, et al. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196.
2. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, et al. (2004) Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430: 686-689.
3. Valenzano DR, Terzibasi E, Genade T, Cattaneo A, Domenici L, et al. (2006) Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr Biol 16: 296-300.
4. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220.
5. Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, et al. (2005) Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 37: 349-350.
6. Anekonda TS, (2006) Resveratrol-a boon for treating Alzheimer's disease? Brain Res Rev 52: 316-326.
7. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342.
8. Baur JA, Sinclair DA, (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506.
9. Bishop NA, Guarente L, (2007) Genetic links between diet and lifespan: shared mechanisms from yeast to humans. Nat Rev Genet 8: 835-844.
10. Mair W, Dillin A, (2008) Aging and survival: the genetics of life span extension by dietary restriction. Annu Rev Biochem 77: 727-754.
11. Hansen M, Taubert S, Crawford D, Libina N, Lee SJ, et al. (2007) Lifespan extension by conditions that inhibit translation in Caenorhabditis elegans. Aging Cell 6: 95-110.
12. Zid BM, Rogers AN, Katewa SD, Vargas MA, Kolipinski MC, et al. (2009) 4E-BP extends lifespan upon dietary restriction by enhancing mitochondrial activity in Drosophila. Cell 139: 149-160.
13. Vellai T, Takacs-Vellai K, Zhang Y, Kovacs AL, Orosz L, et al. (2003) Genetics: influence of TOR kinase on lifespan in C. elegans. Nature 426: 620.
14. Kapahi P, Zid B, (2004) TOR pathway: linking nutrient sensing to life span. Sci Aging Knowledge Environ 2004: PE34.
15. Kaeberlein M, Burtner CR, Kennedy BK, (2007) Recent developments in yeast aging. PLoS Genet 3: e84.
16. Pan KZ, Palter JE, Rogers AN, Olsen A, Chen D, et al. (2007) Inhibition of mRNA translation extends lifespan in Caenorhabditis elegans. Aging Cell 6: 111-119.
17. Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, et al. (2009) Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 326: 140-144.
18. Bjedov I, Toivonen JM, Kerr F, Slack C, Jacobson J, et al. (2010) Mechanisms of Life Span Extension by Rapamycin in the Fruit Fly Drosophila melanogaster. Cell Metab 11: 35-46.
19. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, et al. (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460: 392-395.
20. Ma XM, Blenis J, (2009) Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10: 307-318.
21. Richter JD, Sonenberg N, (2005) Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 433: 477-480.
22. Laplante M, Sabatini DM, (2009) mTOR signaling at a glance. J Cell Sci 122: 3589-3594.
23. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, et al. (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30: 214-226.
24. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, et al. (2008) Metformin slows down aging and extends life span of female SHR mice. Cell Cycle 7: 2769-2773.
25. Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, et al. (2010) Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 9: 188-197.
26. Guertin DA, Sabatini DM, (2009) The pharmacology of mTOR inhibition. Sci Signal 2: pe24.
27. Guertin DA, Sabatini DM, (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9-22.
28. Efeyan A, Sabatini DM, (2009) mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol.
29. Robert F, Pelletier J, (2009) Translation initiation: a critical signalling node in cancer. Expert Opin Ther Targets 13: 1279-1293.
30. Wei M, Fabrizio P, Madia F, Hu J, Ge H, et al. (2009) Tor1/Sch9-regulated carbon source substitution is as effective as calorie restriction in life span extension. PLoS Genet 5: e1000467.
31. Kaeberlein M, (2010) Resveratrol and rapamycin: are they anti-aging drugs? Bioessays 32: 96-99.
32. Delmas D, Jannin B, Cherkaoui Malki M, Latruffe N, (2000) Inhibitory effect of resveratrol on the proliferation of human and rat hepatic derived cell lines. Oncol Rep 7: 847-852.
33. Sonenberg N, Hershey JWB, Mathews MB, (2000) Translational control of gene expression.
34. Raught B, Gingras AC, Gygi SP, Imataka H, Morino S, et al. (2000) Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI. Embo J 19: 434-444.
35. Corton JM, Gillespie JG, Hawley SA, Hardie DG, (1995) 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 229: 558-565.
36. Vlahos CJ, Matter WF, Hui KY, Brown RF, (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269: 5241-5248.
37. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, et al. (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110: 177-189.
38. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, et al. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163-175.
39. Wek RC, Jiang HY, Anthony TG, (2006) Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 34: 7-11.
40. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK, (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32: 1377-1382.
41. Asensi M, Medina I, Ortega A, Carretero J, Bano MC, et al. (2002) Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 33: 387-398.
42. Goldberg DM, Yan J, Soleas GJ, (2003) Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 36: 79-87.
43. Yu C, Shin YG, Chow A, Li Y, Kosmeder JW, et al. (2002) Human, rat, and mouse metabolism of resveratrol. Pharm Res 19: 1907-1914.
44. Lancon A, Delmas D, Osman H, Thenot JP, Jannin B, et al. (2004) Human hepatic cell uptake of resveratrol: involvement of both passive diffusion and carrier-mediated process. Biochem Biophys Res Commun 316: 1132-1137.
45. Armour SM, Baur JA, Hsieh SN, Land-Bracha A, Thomas SM, et al. (2009) Inhibition of Mammalian S6 Kinase by Resveratrol Suppresses Autophagy. AGING 1: 515-528.
46. Dolinsky VW, Chan AY, Robillard Frayne I, Light PE, Des Rosiers C, et al. (2009) Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 119: 1643-1652.
47. Ghosh HS, McBurney M, Robbins PD, (2010) SIRT1 negatively regulates the mammalian target of rapamycin. PLoS One 5: e9199.
48. Bishayee A, (2009) Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res (Phila) 2: 409-418.
49. Bishayee A, Dhir N, (2009) Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem Biol Interact 179: 131-144.
50. Treiber G, (2009) mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther 9: 247-261.
51. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL, (2009) Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys 486: 95-102.
52. Campisi J, Yaswen P, (2009) Aging and cancer cell biology, 2009. Aging Cell 8: 221-225.
53. Liu T, Liu PY, Marshall GM, (2009) The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 69: 1702-1705.
54. Novoa I, Zhang Y, Zeng H, Jungreis R, Harding HP, et al. (2003) Stress-induced gene expression requires programmed recovery from translational repression. EMBO J 22: 1180-1187.
55. Rajasekhar VK, Viale A, Socci ND, Wiedmann M, Hu X, et al. (2003) Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell 12: 889-901.
56. Hursting SD, Smith SM, Lashinger LM, Harvey AE, Perkins SN, (2010) Calories and carcinogenesis: lessons learned from 30 years of calorie restriction research. Carcinogenesis 31: 83-89.
57. Kalaany NY, Sabatini DM, (2009) Tumours with PI3K activation are resistant to dietary restriction. Nature 458: 725-731.
58. Luong N, Davies CR, Wessells RJ, Graham SM, King MT, et al. (2006) Activated FOXO-mediated insulin resistance is blocked by reduction of TOR activity. Cell Metab 4: 133-142.
59. Jimenez RH, Boylan JM, Lee JS, Francesconi M, Castellani G, et al. (2009) Rapamycin response in tumorigenic and non-tumorigenic hepatic cell lines. PLoS One 4: e7373.
60. Lomenick B, Hao R, Jonai N, Chin RM, Aghajan M, et al. (2009) Target identification using drug affinity responsive target stability (DARTS). Proc Natl Acad Sci U S A 106: 21984-21989.
61. Pirola L, Frojdo S, (2008) Resveratrol: one molecule, many targets. IUBMB Life 60: 323-332.
62. Um JH, Park SJ, Kang H, Yang S, Foretz M, et al. (2010) AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 59: 554-563.
63. Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, et al. (2010) AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem 285: 9100-9113.
64. Lin JN, Lin VC, Rau KM, Shieh PC, Kuo DH, et al. (2010) Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation. J Agric Food Chem 58: 1584-1592.
65. Puissant A, Robert G, Fenouille N, Luciano F, Cassuto JP, et al. (2010) Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res 70: 1042-1052.
66. Zhang J, (2006) Resveratrol inhibits insulin responses in a SirT1-independent pathway. Biochem J 397: 519-527.
67. Kaeberlein M, McDonagh T, Heltweg B, Hixon J, Westman EA, et al. (2005) Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 280: 17038-17045.
68. Kaeberlein M, Kennedy BK, (2007) Does resveratrol activate yeast Sir2 in vivo? Aging Cell 6: 415-416.
69. Beher D, Wu J, Cumine S, Kim KW, Lu SC, et al. (2009) Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 74: 619-624.
70. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, et al. (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285: 8340-8351.
71. Solomon JM, Pasupuleti R, Xu L, McDonagh T, Curtis R, et al. (2006) Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol 26: 28-38.
72. Kabra N, Li Z, Chen L, Li B, Zhang X, et al. (2009) SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem 284: 18210-18217.
73. Nie Y, Erion DM, Yuan Z, Dietrich M, Shulman GI, et al. (2009) STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nat Cell Biol 11: 492-500.
74. Liu M, Wilk SA, Wang A, Zhou L, Wang RH, et al. (2010) Resveratrol Inhibits mTOR Signaling by Promoting the Interaction between mTOR and DEPTOR. J Biol Chem 285: 36387-36394.
75. Proud CG, (2005) eIF2 and the control of cell physiology. Semin Cell Dev Biol 16: 3-12.
76. Pitot HC, Peraino C, Morse PA Jr, Potter VR, (1964) Hepatomas in Tissue Culture Compared with Adapting Liver in Vivo. Natl Cancer Inst Monogr 13: 229-245.
77. Ballard FJ, Read LC, Francis GL, Bagley CJ, Wallace JC, (1986) Binding properties and biological potencies of insulin-like growth factors in L6 myoblasts. Biochem J 233: 223-230.
78. Montgomery JL, Harper WM Jr, Miller MF, Morrow KJ Jr, Blanton JR Jr, (2002) Measurement of protein synthesis and degradation in C2C2) myoblasts using extracts of muscle from hormone treated bovine. Methods Cell Sci 24: 123-129.
79. Anand P, Gruppuso PA, (2006) Rapamycin inhibits liver growth during refeeding in rats via control of ribosomal protein translation but not cap-dependent translation initiation. J Nutr 136: 27-33.
80. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM, (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7: e38.